Helicobacter pylori and EBV in gastric carcinomas: Methylation status and microsatellite instability

Table 3 Associations between gene methylation status and clinicopathological features, age, H. pylori, MSI and EBV n (%)

	Methylated genes
	Total	CDH1	P-value	DAP-kinase	P-value	COX2	P-value	hMLH1	P-value	CDKN2A	P-value
Mean age (yr)		60.2		59.9		60.9		63.1		62.5
Age group (yr)
≤ 50	19	10 (52.6)	0.883	8 (44.4)	0.282	9 (50)	0.179	6 (33.3)	0.903	3 (15.8)	0.0351
> 50	69	35 (50.7)		41 (58.6)		45 (67.2)		21 (31.8)		29 (42)
Gender
Male	59	30 (50.8)	0.938	33 (55.9)	0.946	34 (59.6)	0.289	21 (35)	0.787	21 (35.6)	0.830
Female	29	15 (51.7)		16 (55.2)		20 (71.4)		11 (37.9)		11 (37.9)
Nodal metastases
Absent	17	8 (47.1)	0.708	9 (50)	0.586	11 (64.7)	0.910	6 (33.3)	0.903	6 (33.3)	0.764
Present	71	37 (52.1)		40 (57.1)		43 (63.2)		21 (31.8)		26 (37.1)
Tumor site
Cardia	13	8 (61.5)	0.855	9 (69.2)	0.427	10 (83.3)	0.228	4 (30.8)	0.304	8 (61.5)	0.266
Antrum	38	21 (55.3)		20 (52.6)		21 (56.8)		14 (37.8)		14 (35.9)
Body	10	5 (50)		7 (70)		7 (70)		1 (11.1)		4 (40)
Misted	3	3 (100)		2 (66.7)		3 (100)		0		0
Laurèn
Diffuse	30	17 (56.7)	0.503	10 (33.3)	0.628	19 (63.3)	0.973	8 (27.6)	0.481	10 (33.3)	0.628
Intestinal	57	28 (49.1)		22 (38.6)		34 (63)		19 (35.2)		22 (38.6)
Mixed	1	0 (0.0)		0		1 (100)		0		0
H. pylori
CagA+	55	31 (56.4)	0.261	30 (54.5)	0.782	35 (66)	0.536	15 (28.8)	0.41	22 (40)	0.468
CagA-	34	15 (44.1)		19 (57.6)		19 (59.4)		12 (37.5)		11 (32.4)
MS status
MSI	14	5 (35.7)	0.174	4 (26.7)	0.0121	8 (53.3)	0.349	10 (66.7)	0.0011	4 (26.7)	0.405
MSS	72	40 (55.6)		44 (62)		45 (66.2)		16 (23.5)		27 (38)
EBV
Positive	5	1 (20)	0.101	4 (80)	0.346	4 (80)	0.694	0	0.179	3 (60)	0.462
Negative	48	28 (58.3)		28 (58.3)		33 (71.7)		15 (31.9)		21 (42.9)

¹Statistically significant result.